Floatz logo

Yttrium-90

Secondary Malignant Neoplasm of Liver

University of MinnesotaradiopharmaceuticalN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Secondary Malignant Neoplasm of Liver cohort.

Asset / SponsorPhaseRating
Tuvonralimab
Peking University Cancer Hospital & Institute
Phase 2CCC
Eloxatin
Peking University Cancer Hospital & Institute
Phase 2CCC
Iparomlimab
Peking University Cancer Hospital & Institute
Phase 2CCC
Capecitabine
Peking University Cancer Hospital & Institute
Phase 2CCC

Same molecule, other indications

Yttrium-90 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
Liver Cancer (Locally Advanced or Metastatic)Dormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →